SCHEMBL6088032

SCHEMBL6088032

COC(=O)C1CCCC(O)N1C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
PREP P48147 3/20 0.39
FKBP1A P62942 2/20 0.38
EPHX1 P07099 1/20 0.38
HSD17B10 Q99714 1/20 0.37
HPGD P15428 1/20 0.36
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
PTPN1 P18031 1/20 0.36
LMNA P02545 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MMP2 P08253 1/20 0.34
ANPEP P15144 1/20 0.34
POLB P06746 1/20 0.34
ALDH1A1 P00352 1/20 0.33
KLK5 Q9Y337 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25867318 1.00 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPFKBP1A
SCHEMBL1104531 0.91 CHRM2 (0.49) CHRM2CHRM1CHRM3PREPFKBP1A
SCHEMBL31134214 0.91 CHRM2 (0.49) CHRM2CHRM1CHRM3PREPFKBP1A
SCHEMBL17014473 0.91 CHRM2 (0.49) CHRM2CHRM1CHRM3PREPFKBP1A
SCHEMBL5832187 0.91 CHRM2 (0.49) CHRM2CHRM1CHRM3PREPFKBP1A
SCHEMBL16577415 0.91 CHRM2 (0.49) CHRM2CHRM1CHRM3PREPFKBP1A
SCHEMBL15773749 0.91 CHRM2 (0.49) CHRM2CHRM1CHRM3PREPFKBP1A
SCHEMBL21441862 0.85 CHRM2 (0.43) CHRM2CHRM1CHRM3PREPFKBP1A
SCHEMBL18018299 0.85 CHRM2 (0.43) CHRM2CHRM1CHRM3PREPFKBP1A
SCHEMBL6126949 0.84 CHRM2 (0.50) CHRM2CHRM1CHRM3PREPFKBP1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138395-B2 Interleukin-1β converting enzyme inhibitors THE PROCTER & GAMBLE COMPANY (US) 2006-11-21 US disclosed
EP-1511749-A1 NOVEL INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2005-03-09 EP disclosed
US-20040014753-A1 Novel interleukin-1beta converting enzyme inhibitors THE PROCTER & GAMBLE COMPANY 2004-01-22 US disclosed
WO-2003104231-A1 NOVEL INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014753-A1 Novel interleukin-1beta converting enzyme inhibitors IL1B, IL1RN, IL1R1 CHRM2 1976/4885CHRM1 1341/4885CHRM3 2321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.